Tag: ESC 2018

ESC 2018: TMVI associated with “excellent outcomes” for valve-in-valve procedures

New results from the TMVR (Transcatheter mitral valve replacement) Registry show that patients with a degenerated bioprosthesis who undergo transcatheter mitral valve implantation (TMVI)...

ESC 2018: More evidence that FFRCT is an effective approach for...

Bjarne L Nørgaard (Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark) and colleagues report in the Journal of the American College of Cardiology (JACC)...

ESC 2018: First US FDA-approved study shows TAVI is safe for...

The LRT (Low Risk TAVR) trial did not find any significant differences in the rate of all-cause mortality between low-risk patients undergoing transcatheter aortic...

ESC 2018: Novel imaging biomarker can predict risk of cardiac mortality

Milind Desai (Cleveland Clinic, Cleveland, USA) and colleagues have identified a novel imaging biomarker that has been found to be able to predict all-cause...

ESC 2018: All-cause mortality in cardiogenic shock multivessel PCI only increased...

One-year data from the CULPRIT-SHOCK trial indicate that there is no significant difference in all-cause mortality between cardiogenic shock patients undergoing immediate multivessel percutaneous...

ESC 2018: Ticagrelor monotherapy approach does not challenge current DAPT approach

The GLOBAL LEADERS trial, simultaneously published in the Lancet and presented at the 2018 European Society of Cardiology (ESC) Congress (25–29 August, Munich, Germany),...

ESC 2018: No difference in MACE between drug-coated balloons and drug-eluting...

The 12-months results of the BASKET-SMALL 2 study, which were presented at the 2018 European Society of Cardiology (ESC) Congress (25–29 August, Munich, Germany),...

ESC 2018: Higher all-cause mortality with Orsiro at five years than...

According to the five-year results of the BIOSCIENCE trial, sirolimus-eluting stents with a biodegradable polymer (Orsiro, Biotronik) have a similar overall safety and efficacy...

ESC 2018: MitraClip makes “absolutely no difference” for the prognosis...

The first randomised controlled trial to compare percutaneous edge-to-edge repair (MitraClip, Abbott) with medical therapy alone in patients with secondary mitral regurgitation (to heart...

ESC 2018: Greater use of PCI for high SYNTAX score patients...

The final results of the FUTURE (Functional testing underlying revascularisation) trial indicate that more patients with multivessel disease and a high SYNTAX score (>32)...

ESC 2018: DAPT score “not generalisable” to a nationwide population

A new study has found that the dual antiplatelet therapy (DAPT) score, which is recommended by both US and European guidelines, did not adequately...

ESC 2018: Non-atherosclerotic spontaneous coronary artery dissection predominantly affects young to...

Data from the Canadian Spontaneous Coronary Artery Disease (CanSCAD) study indicate that the majority of patients with non-atherosclerotic spontaneous coronary artery dissection are young...

ESC 2018: Cardioskin launched

WeHealth, by Servier, has launched Cardioskin—a connected solution that is designed to function as an ambulatory wearable 15-lead ECG—at the 2018 European Society of...

Twenty thousand patients have now been treated with RenalGuard therapy

RenalGuard Solutions has announced the treatment of 20,000 patients with RenalGuard for the prevention of contrast-induced nephropathy. A press release reports that the system,...

ESC 2018: Society calls for abstract submissions for its next congress

The European Society of Cardiology (ESC) has released a new video, see below, that outlines the reasons why physicians should consider submitting an abstract...